RNA aptamers and methods for identifying the same
RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.
1. A method of modulating the biological activity of Ang2 comprising administering to a host an RNA aptamer that binds to Ang2, the aptamer comprising a secondary structure, wherein the secondary structure comprises, in a 5′ to 3′ direction, a first stem region, a first loop region, a second stem region, a second loop region, a third loop region, a third stem region, a fourth loop region, and a fifth loop region, and wherein the aptamer further comprises a consensus sequence comprising AUCAGC.
2. The method of claim 1 , wherein the aptamer comprises at least one 2′-modified nucleotide.
3. The method of claim 2 , wherein the aptamer comprises at least one modified nucleotide selected from the group consisting of a 2′-halo-modified nucleotide, and a 2′-O-alkyl-modified nucleotide.
4. The method of claim 2 , wherein the aptamer comprises at least one 2′-fluorocytidine or one 2′-fluorouridine.
5. The method of claim 2 , wherein the aptamer comprises cytidines that are all 2′-deoxy-2′-fluorocytidine, or uridines that are all 2′-deoxy-2′-fluorouridine.
6. The method of claim 2 , wherein the aptamer comprises at least one 2′-O-alkyl-modified nucleotide.
7. The method of claim 1 , wherein the aptamer further comprises a covalently linked carrier selected from the group consisting of a soluble polymer, a biodegradable polymer, polyethylene glycol, and cholesterol.
8. The method of claim 1 , wherein the aptamer is administered orally, topically to a vascular tissue, intravenously, intraperitoneally, intramuscularly, subcutaneously, intra-cavity, transdermally, or by peristaltic techniques.
9. The method of claim 8 , wherein topical administration comprises coating or impregnating a blood vessel tissue with a gel comprising the aptamer and implanting the coated or impregnated vessel in place of a damaged or diseased vessel tissue segment in the host.
10. The method of claim 8 , wherein topical administration comprises delivery via a catheter to a vessel or vessels in the host.
11. The method of claim 8 , wherein topical administration comprises pumping an aptamer composition of the present invention into a vessel that is to be implanted into the host.
12. The method of claim 1 , wherein the aptamer is administered at a dosage from about 1 μg/kg body weight to about 1 mg/kg body weight.
13. The method of claim 1 , wherein the aptamer comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 168, 170, 171, 175, 177, 179, and 183.
14. The method of claim 13 , wherein the aptamer comprises the nucleotide sequence of SEQ ID NO: 168 or a truncate thereof.
15. The method of claim 1 , wherein the aptamer comprises the nucleotide sequence SEQ ID NO: 187.
16. A method of modulating the biological activity of Ang2 comprising administering to a host an RNA aptamer that binds to Ang2, the aptamer comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 169, 172, 173, 174, 176, 178, 180-182, and 184-186.
17. The method of claim 16 , wherein the aptamer comprises at least one 2′-modified nucleotide.
18. The method of claim 17 , wherein the aptamer comprises at least one modified nucleotide selected from the group consisting of a 2′-halo-modified nucleotide, and a 2′-O-alkyl-modified nucleotide.
19. The method of claim 17 , wherein the aptamer comprises at least one 2′-fluorocytidine or one 2′-fluorouridine.
20. The method of claim 17 , wherein the aptamer comprises cytidines that are all 2′-deoxy-2′-fluorocytidine, or uridines that are all 2′-deoxy-2′-fluorouridine.
21. The method of claim 17 , wherein the aptamer comprises at least one 2′-O-alkyl-modified nucleotide.
22. The method of claim 16 , wherein the aptamer further comprises a covalently linked carrier selected from the group consisting of a soluble polymer, a biodegradable polymer, polyethylene glycol, and cholesterol.
23. The method of claim 16 , wherein the aptamer is administered orally, topically to a vascular tissue, intravenously, intraperitoneally, intramuscularly, subcutaneously, intra-cavity, transdermally, or by peristaltic techniques.
24. The method of claim 23 , wherein topical administration comprises coating or impregnating a blood vessel tissue with a gel comprising the aptamer and implanting the coated or impregnated vessel in place of a damaged or diseased vessel tissue segment in the host.
25. The method of claim 24 , wherein topical administration comprises delivery via a catheter to a vessel or vessels in the host.
26. The method of claim 24 , wherein topical administration comprises pumping an aptamer composition of the present invention into a vessel that is to be implanted into the host.
27. The method of claim 16 , wherein the aptamer is administered at a dosage from about 1 μg/kg body weight to about 1 mg/kg body weight.
28. The method of claim 16 , wherein the aptamer is a truncate of SEQ ID NOs: 169, 172, 173, 174, 176, 178, 180-182, or 184-186.